Condition
Leptomeningeal Neoplasm
Total Trials
3
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
2Total
P 1 (2)
Trial Status
Recruiting2
Active Not Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT03025256Phase 1Recruiting
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
NCT04250545Phase 1Active Not RecruitingPrimary
Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer
NCT04988009Recruiting
Patient Perceptions Around Quality of Care Through Telemedicine in Neuro-Oncology
Showing all 3 trials